If you have ever blanked on extrapyramidal side effects mid-viva, the fix is not more re-reading — it is an antipsychotic side effects mnemonic that survives exam pressure. Antipsychotics are the most side-effect-dense drug class in psychiatry, and examiners know it: EPS profiles, anticholinergic burden, metabolic risk, hyperprolactinaemia, QTc prolongation and clozapine's agranulocytosis all show up in MCQs, case discussions and clinical stations.
This article consolidates the adverse-effect landscape into memory hooks that actually stick — the classic anticholinergic rhyme, the syndrome-by-syndrome anchors for EPS, a typical-versus-atypical comparison table, and the one confusion (akathisia vs parkinsonism) that costs candidates marks in every exam diet.
Antipsychotic side effect mnemonics: the anticholinergic rhyme
The oldest and best-established mnemonic in psychopharmacology describes classical anticholinergic toxicity: "blind as a bat, dry as a bone, red as a beet, mad as a hatter, hot as a hare, the bowel and bladder never fail, and the heart runs pure." Map each clause:
- Blind as a bat — cycloplegia and blurred vision from ciliary muscle blockade.
- Dry as a bone — anhidrosis and dry mouth (xerostomia); the symptom patients complain about most.
- Red as a beet — cutaneous vasodilation and flushing.
- Mad as a hatter — confusion, agitation, delirium, and at extreme doses hallucinations — which is why anticholinergic delirium is on the differential for any acutely confused patient on antipsychotics or antiparkinsonian drugs.
- Hot as a hare — hyperthermia from lost sweating.
- Bowel and bladder never fail — ileus/constipation and urinary retention. Constipation is not trivial: anticholinergic burden contributes to fatal colitis, particularly with clozapine.
- Heart runs pure — tachycardia (reflex plus atropine-like effect).
Practically: every "sedating" antipsychotic (chlorpromazine, olanzapine, quetiapine) carries meaningful anticholinergic load, and the burden stacks when you add procyclidine, promethazine or amitriptyline on top. Ask about constipation and urinary retention in any patient on a cocktail — this is a clinical pearl as much as an exam one.
Extrapyramidal side effects: four syndromes, four anchors
EPS cluster under dopamine D2 blockade in the nigrostriatal pathway. Anchor each syndrome to its defining feature:
- Dystonia — sudden, sustained muscle contraction. Anchor: timing and shape — typically within hours to days of the first dose (oculogyric crisis, torticollis, laryngospasm), most common in young men. Treatment: anticholinergic (procyclidine/benztropine) IV/IM; never "wait and see" with laryngeal involvement.
- Akathisia — inner restlessness with an irresistible urge to move. Anchor: "I can't sit still because something is screaming at me to move." Subjective distress is the hallmark, objective rocking/foot-tapping the sign. Frequently misread as agitation or anxiety — and a recognised driver of non-adherence and, in severe cases, suicidality.
- Drug-induced parkinsonism — the rigid quartet: bradykinesia, rigidity, resting tremor, masked facies. Anchor: signs, not feelings — the patient may not notice; the examiner sees the cogwheeling. Onset typically weeks, and it does not improve with more movement.
- Tardive dyskinesia — delayed-onset (months to years) choreoathetoid movements, classically orofacial: lip-smacking, tongue protrusion, chewing. Anchor: late + involuntary + cannot be suppressed. Risk rises with duration, dose, older age and cumulative exposure; once established, outcomes are better if caught early (VMAT2 inhibitors such as valbenazine are the evidence-based treatment).
Two pathway reminders that examiners love: antipsychotic-induced hyperprolactinaemia comes from D2 blockade at the tuberoinfundibular tract (raised prolactin → galactorrhoea, amenorrhoea, sexual dysfunction, reduced bone density), and the metabolic syndrome from H1/5-HT2C blockade plus histaminergic appetite effects (weight gain, dyslipidaemia, type 2 diabetes — olanzapine and clozapine sit at the top of the risk league).
Typical versus atypical: what actually differs
The blanket claim "atypicals have no EPS" is false and examiners exploit it — risperidone and paliperidone carry EPS rates approaching high-potency typicals at moderate doses. The comparison that holds up:
| Class / drug | EPS risk | Metabolic risk | Prolactin | Other defining risk |
|---|---|---|---|---|
| High-potency typical (haloperidol, flupentixol) | High | Low | High | QTc prolongation; acute dystonia in the first days |
| Low-potency typical (chlorpromazine) | Moderate | Moderate | Moderate | Heavy anticholinergic/sedation burden; orthostatic hypotension (alpha-1 blockade) |
| Risperidone / paliperidone | Dose-dependent, notable | Low–moderate | Highest of the atypicals | Hyperprolactinaemia is the classic exam answer |
| Olanzapine | Low–moderate | Highest (with clozapine) | Low | Weight gain and new-onset diabetes; also anticholinergic load |
| Quetiapine | Low | Moderate | Low (fast off-rate) | Sedation, orthostasis; QTc at higher exposures |
| Clozapine | Lowest | Highest overall | Low | Agranulocytosis (≈0.8–0.9% in the first 6–12 months, hence mandatory blood monitoring), plus myocarditis, seizures, severe constipation/ileus |
| Aripiprazole | Low | Low | Low — can lower prolactin | Partial agonism: akathisia is the signature adverse effect |
Two more system-level anchors: QTc prolongation (risk of torsades de pointes — check ECG when using IV loading, high doses, or drugs like ziprasidone/pimozide/haloperidol IV, and with interacting QT-prolonging agents) and neuroleptic malignant syndrome — the rare emergency triad of rigidity + hyperthermia + autonomic instability with markedly raised CK, requiring immediate cessation and supportive care. NICE CG178 (antipsychotic management) is the current UK standard for monitoring and choice — check it for the latest thresholds before exam day.
Repetition does the rest: Preppsy's flashcard decks drill these pairings on a spaced schedule, so the association "risperidone → prolactin" becomes reflexive rather than reconstructed under time pressure.
The classic framing: "chemical lobotomy" and why to handle it carefully
Older textbooks and some patients use the phrase "chemical lobotomy" for antipsychotic sedation, blunting and demotivation — the subjective experience of over-sedation and emotional flattening, historically more associated with high-potency typicals and depot responses. Use the phrase to remember the clinical picture (sedation, reduced goal-directed drive, social withdrawal from over-treatment) but never as a description you endorse: it is stigmatising, inaccurate about mechanism, and in an exam it reads as poor pharmacological reasoning. The precise answer is that oversedation, akathisia and depressant effects of co-prescribed anticholinergics can mimic negative symptoms — and distinguishing secondary negative symptoms from primary ones is itself a high-yield clinical skill.
Exam trap: confusing akathisia with parkinsonism
Both start on antipsychotics; both get wrongly labelled "agitation"; the treatments differ completely. Akathisia = too much movement drive — the patient cannot sit still, feels inner torment, paces, rocks, crosses and uncrosses legs, and often tells you so. Parkinsonism = too little — bradykinesia, rigidity, resting tremor, masked facies; the patient may deny any problem while you observe the cogwheel. Vignette tells: "reports feeling restless and unable to stay seated" = akathisia (consider dose reduction, propranolol, or a low-dose anticholinergic); "moved slowly with tremor at rest" = parkinsonism (anticholinergic or amantadine, dose reduction). Treating akathisia as anxiety — or worsening it with an anticholinergic that adds delirium risk — is the trap. Ask one question: "Do you feel restless, or does your body move on its own?"
Frequently asked questions
What is a good mnemonic for antipsychotic side effects?
Use two layers. For anticholinergic burden, the classic rhyme: "blind as a bat, dry as a bone, red as a beet, mad as a hatter, hot as a hare, the bowel and bladder never fail, and the heart runs pure." For EPS, anchor each syndrome to its trigger and tempo: dystonia (early, first days, young men), akathisia (subjective restlessness), parkinsonism (bradykinesia/rigidity/tremor), tardive dyskinesia (late, involuntary, orofacial). Layer class-level rules on top: typicals → EPS and prolactin; atypicals (especially olanzapine/clozapine) → metabolic; clozapine → blood dyscrasias requiring monitoring.
What is the difference between typical and atypical antipsychotic side effects?
Typical antipsychotics, particularly high-potency agents like haloperidol, cause more extrapyramidal symptoms and hyperprolactinaemia but less weight gain. Atypicals generally cause fewer EPS (though risperidone is a notable exception) and less prolactin elevation, but carry greater metabolic risk — weight gain, dyslipidaemia and diabetes, worst with olanzapine and clozapine — plus agent-specific risks such as clozapine's agranulocytosis and myocarditis. Both classes can prolong the QTc interval and cause anticholinergic and antiadrenergic effects.
How do you tell akathisia from drug-induced parkinsonism?
Ask about inner experience and watch for objective signs. Akathisia is a subjective urge to move with visible rocking, pacing or foot-tapping, and the patient is distressed by it. Drug-induced parkinsonism is largely objective — bradykinesia, cogwheel rigidity, resting tremor, masked facies — with the patient often unaware. Timing supports the distinction: parkinsonism typically emerges over weeks, akathisia within days to weeks of a dose change. Confirmation: both improve with dose reduction, but akathisia responds best to propranolol or a short anticholinergic course, whereas parkinsonism responds to an anticholinergic or amantadine.
Which antipsychotic has the highest risk of agranulocytosis?
Clozapine — roughly 0.8–0.9% of patients develop severe neutropenia, concentrated in the first 6–12 months of treatment, which is why mandatory blood-count monitoring is built into its prescribing (REMS in the US, the CLOZARIL monitoring programme in the UK). Risk after one year falls to about 1% or less cumulative but does not disappear, so monitoring continues. Any patient on clozapine with fever or sore throat needs an urgent full blood count — agranulocytosis is an exam answer and an emergency.
Key takeaways
- Memorise the anticholinergic rhyme once — it covers blur, dryness, flushing, delirium, hyperthermia, ileus/retention and tachycardia in one hook.
- Anchor EPS by tempo: dystonia (hours–days), akathisia (subjective restlessness), parkinsonism (weeks, objective signs), tardive dyskinesia (months–years, orofacial chorea).
- Class rules with exceptions: typicals → EPS/prolactin; atypicals → metabolic; risperidone behaves like a typical for prolactin and EPS.
- Clozapine = agranulocytosis with mandatory monitoring, plus myocarditis, seizures and ileus risk.
- QTc and NMS are the two emergencies: ECG-check high-risk regimens; NMS = rigidity + hyperthermia + autonomic instability + raised CK.
- Never confuse akathisia with parkinsonism — one is too much movement drive, the other too little, and the treatments differ.
Turn these hooks into reflexes with spaced drilling, and put them to work against real vignettes on Preppsy's MRCPsych prep.
Cover image: “Cover image” (CC0) via stocksnap.
